Back to today’s briefing

Story perspectives

Eli Lilly to Acquire Centessa Pharmaceuticals for $7.8 Billion

3/31/2026

36 7 Full Breakdown

Summary

Story summary

Eli Lilly and Company will acquire Centessa Pharmaceuticals for up to $7.8 billion.
Centessa is valued at $38 per share.
The transaction includes a $6.3 billion upfront payment.
Centessa's lead drug cleminorexton (ORX750) is in mid-stage trials for narcolepsy and idiopathic hypersomnia, reflecting a growing narcolepsy drug market.
The deal is expected to close in the third quarter of 2026.

1 of 1

Story summary

Eli Lilly and Company will acquire Centessa Pharmaceuticals for up to $7.8 billion.
Centessa is valued at $38 per share.
The transaction includes a $6.3 billion upfront payment.
Centessa's lead drug cleminorexton (ORX750) is in mid-stage trials for narcolepsy and idiopathic hypersomnia, reflecting a growing narcolepsy drug market.
The deal is expected to close in the third quarter of 2026.